What are the short-term and long-term priorities for your company?
Near-term we are focused on moving our lead product candidate, entinostat, in to a phase 3 clinical trial for post-menopausal women with estrogen receptor-positive (ER+) metastatic breast cancer (MBC). Long-term our goal is to help overcome the problem of resistance seen with oncology treatments in multiple indications.
How does your company go about differentiating yourselves from the competition?
Unlike many small, private companies we have a robust clinical development program that includes placebo-controlled, randomized phase 2 clinical trials aimed at developing rigorous data to support the potential for our product in improving clinical outcomes in oncology indications. We will be announcing our data in September from a randomized, placebo-controlled phase 2 clinical trial in post-menopausal women with ER+ MBC.
What is the most challenging part of raising money and seeking collaborations?
The most challenging part of raising money these days is the uncertainty of the markets. Both potential investors and partners see the potential for entinostat in working in combination to help overcome the issue of resistance that is seen with targeted oncology treatments.
Tell us something about your company that investors might not know.
The National Cancer Institute is funding more than 10 further clinical trials on entinostat in other combinations and in other cancer types which represents the equivalent of at least $40 million additional spend to develop opportunities to expand the entinostat commercial opportunity.
Syndax Pharmaceuticals will be participating in One-on-One Partnering at the event. Log in to view their profile and request a meeting, and don’t miss their company presentation at BIO Investor Forum!